Bank of New York Mellon’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.57M | Buy |
684,539
+394,671
| +136% | +$1.51M | ﹤0.01% | 2809 |
|
|
2026
Q1 | $1.36M | Sell |
289,868
-38,380
| -12% | -$195K | ﹤0.01% | 3026 |
|
|
2025
Q4 | $1.4M | Buy |
328,248
+75,589
| +30% | +$287K | ﹤0.01% | 3052 |
|
|
2025
Q3 | $806K | Hold |
252,659
| – | – | ﹤0.01% | 3339 |
|
|
2025
Q2 | $574K | Buy |
252,659
+10,679
| +4% | +$17.2K | ﹤0.01% | 3434 |
|
|
2025
Q1 | $154K | Hold |
241,980
| – | – | ﹤0.01% | 3944 |
|
|
2024
Q4 | $249K | Sell |
241,980
-2
| -0% | -$2 | ﹤0.01% | 3868 |
|
|
2024
Q3 | $286K | Hold |
241,982
| – | – | ﹤0.01% | 3791 |
|
|
2024
Q2 | $295K | Buy |
241,982
+1
| +0% | +$2 | ﹤0.01% | 3818 |
|
|
2024
Q1 | $528K | Sell |
241,981
-24,855
| -9% | -$45.9K | ﹤0.01% | 3496 |
|
|
2023
Q4 | $414K | Hold |
266,836
| – | – | ﹤0.01% | 3662 |
|
|
2023
Q3 | $344K | Buy |
266,836
+234,970
| +737% | +$370K | ﹤0.01% | 3750 |
|
|
2023
Q2 | $54.8K | Sell |
31,866
-4,286
| -12% | -$7.12K | ﹤0.01% | 4165 |
|
|
2023
Q1 | $54.6K | Hold |
36,152
| – | – | ﹤0.01% | 4179 |
|
|
2022
Q4 | $57.8K | Sell |
36,152
-33
| -0.1% | -$49 | ﹤0.01% | 4215 |
|
|
2022
Q3 | $52K | Hold |
36,185
| – | – | ﹤0.01% | 4319 |
|
|
2022
Q2 | $66K | Sell |
36,185
-176,108
| -83% | -$337K | ﹤0.01% | 4302 |
|
|
2022
Q1 | $567K | Sell |
212,293
-792
| -0.4% | -$3.04K | ﹤0.01% | 3634 |
|
|
2021
Q4 | $923K | Buy |
213,085
+2,998
| +1% | +$17.6K | ﹤0.01% | 3427 |
|
|
2021
Q3 | $1.07M | Buy |
210,087
+15,591
| +8% | +$83.5K | ﹤0.01% | 3356 |
|
|
2021
Q2 | $1.23M | Sell |
194,496
-2,740
| -1% | -$21.3K | ﹤0.01% | 3281 |
|
|
2021
Q1 | $1.52M | Buy |
197,236
+20,825
| +12% | +$165K | ﹤0.01% | 3082 |
|
|
2020
Q4 | $1.16M | Sell |
176,411
-5,207
| -3% | -$37.2K | ﹤0.01% | 3176 |
|
|
2020
Q3 | $1.21M | Buy |
181,618
+534
| +0.3% | +$3.96K | ﹤0.01% | 3007 |
|
|
2020
Q2 | $1.51M | Sell |
181,084
-14,147
| -7% | -$131K | ﹤0.01% | 2849 |
|
|
2020
Q1 | $1.5M | Buy |
195,231
+6,584
| +3% | +$45.9K | ﹤0.01% | 2700 |
|
|
2019
Q4 | $1.57M | Sell |
188,647
-4,408
| -2% | -$29.7K | ﹤0.01% | 2968 |
|
|
2019
Q3 | $1.43M | Buy |
193,055
+11,293
| +6% | +$111K | ﹤0.01% | 2939 |
|
|
2019
Q2 | $2.04M | Sell |
181,762
-4,744
| -3% | -$49.7K | ﹤0.01% | 2788 |
|
|
2019
Q1 | $2M | Buy |
186,506
+954
| +0.5% | +$14.1K | ﹤0.01% | 2778 |
|
|
2018
Q4 | $2.8M | Buy |
185,552
+11,007
| +6% | +$163K | ﹤0.01% | 2576 |
|
|
2018
Q3 | $3.23M | Buy |
174,545
+19,304
| +12% | +$440K | ﹤0.01% | 2604 |
|
|
2018
Q2 | $3.55M | Buy |
155,241
+19,749
| +15% | +$504K | ﹤0.01% | 2554 |
|
|
2018
Q1 | $3.85M | Buy |
135,492
+5,855
| +5% | +$167K | ﹤0.01% | 2484 |
|
|
2017
Q4 | $2.74M | Buy |
129,637
+455
| +0.4% | +$9.43K | ﹤0.01% | 2664 |
|
|
2017
Q3 | $2.35M | Buy |
129,182
+13,405
| +12% | +$209K | ﹤0.01% | 2751 |
|
|
2017
Q2 | $1.79M | Buy |
115,777
+29,319
| +34% | +$442K | ﹤0.01% | 2911 |
|
|
2017
Q1 | $1.49M | Sell |
86,458
-405
| -0.5% | -$5.33K | ﹤0.01% | 3030 |
|
|
2016
Q4 | $955K | Buy |
86,863
+2,698
| +3% | +$32.7K | ﹤0.01% | 3286 |
|
|
2016
Q3 | $1.32M | Buy |
84,165
+12,427
| +17% | +$150K | ﹤0.01% | 3022 |
|
|
2016
Q2 | $733K | Buy |
71,738
+48,474
| +208% | +$553K | ﹤0.01% | 3345 |
|
|
2016
Q1 | $300K | Buy |
23,264
+4,979
| +27% | +$69.1K | ﹤0.01% | 3643 |
|
|
2015
Q4 | $382K | Buy |
+18,285
| New | +$289K | ﹤0.01% | 3634 |
|
Other funds holding CTMX
N
Bank of New York Mellon's CTMX Position: Q2 2026 in Review
Bank of New York Mellon increased its CytomX Therapeutics (CTMX) stake by 136% in Q2 2026, buying an estimated $1.51M and bringing the position to 684,539 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.
Bank of New York Mellon first reported a position in CTMX in Q4 2015 and has held it in 43 quarters since. The position peaked at $3.85M in Q1 2018. 80 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.
- Bank of New York Mellon held 684,539 shares of CytomX Therapeutics worth $2.57M as of Q2 2026.
- Bank of New York Mellon bought 394,671 CytomX Therapeutics shares in Q2 2026, an estimated $1.51M.
- CytomX Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2809 holding.
- Bank of New York Mellon first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 43 quarters since.
- Bank of New York Mellon's CytomX Therapeutics position peaked at $3.85M in Q1 2018.
- 80 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.